Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.
Manuel Hidalgo
No relevant relationships to disclose
Antonio Calles
No relevant relationships to disclose
Dejan Juric
No relevant relationships to disclose
Rodrigo Dienstmann
No relevant relationships to disclose
Desamparados Roda Perez
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Genentech
George R. Blumenschein
Consultant or Advisory Role - Genentech
Research Funding - Genentech
José Baselga
Consultant or Advisory Role - Genentech
Josep Tabernero
Consultant or Advisory Role - Genentech
Andres Cervantes-Ruiperez
Consultant or Advisory Role - Genentech
Antonio Jimeno
No relevant relationships to disclose
Denise Jin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Shuang Bai
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Pavel Gurevich
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Ihsan Nijem
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Scott N. Holden
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
John D Davis
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Wendy Halpern
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Andrea Pirzkall
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Yan Xin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech